Patients, advocates, and care providers are growing increasingly frustrated that new and often very pricey cancer drugs do little to improve patients’ survival, Kaiser Health News reports.
For instance, the 72 cancer therapies approved between 2002 and 2014 only bought patients an extra 2.1 months of life compared with older drugs, researchers have found. And there’s no evidence that two-thirds of the drugs approved in the last two years improve survival at all.
Comments